Oncology AACR 2025: New modalities and remaining challenges Explore the latest advancements and challenges in ADC therapy at AACR 2025: New modalities and remaining challenges
News AACR 2025: Quintet of investigational oncological drugs puts... Ascentage Pharma, specialising in haematological malignancies, has presented results from five preclinical studies at AACR 2025.
News AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncol... Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at AACR 2025.
Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
